Leustatine

Cladribine, the active ingredient in Leustatine, is an antimetabolite presented as an intravenous solution for infusion use. It is employed in the treatment of certain hematologic malignancies and an autoimmune neurological condition, targeting abnormal lymphocyte proliferation in adult patients.

GNH USA supplies Leustatine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality‑controlled shipments across regulated markets with robust cold‑chain logistics where required.

Cladribine is used to target malignant B‑cell disorders and an autoimmune disease by selectively depleting lymphocytes, thereby modifying disease activity.

- Chronic lymphocytic leukemia: reduces disease burden and prolongs progression‑free survival. - Hairy cell leukemia: induces durable remission by eliminating malignant cells. - Multiple sclerosis: decreases relapse rate and slows disability progression in active disease.

Cladribine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Fever: transient elevations in body temperature. - Lymphopenia: reduction in lymphocyte count. - Headache: occasional mild cranial discomfort. - Mild infections: increased susceptibility to common colds.

Serious or Rare Side Effects: - Opportunistic infections: severe infections such as pneumocystis pneumonia. - Severe lymphopenia: profound depletion of immune cells. - Secondary malignancies: rare emergence of new cancers. - Autoimmune hepatitis: liver inflammation of immune origin. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Progressive multifocal leukoencephalopathy: rare viral brain infection.

Cladribine requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform regular CBC to detect lymphopenia. - Assess infection risk: screen for active infections prior to initiation. - Evaluate renal function: adjust use in severe impairment. - Pregnancy considerations: avoid in pregnant women unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, necessitating vigilance to avoid additive toxicity or reduced efficacy.

Major Interactions (Avoid): - Concurrent immunosuppressants: may cause profound immunosuppression. - Live vaccines: increased risk of vaccine‑derived infection. - Other myelosuppressive chemotherapy agents: heightened bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: monitor immune response. - Prophylactic antibiotics: may mask early infection signs. - Antifungal agents: watch for liver enzyme changes.